•http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf
•UpToDate (Pediatric drug information).
•Medimecum (guía de terapia farmacológica).
•http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=67083&formato=pdf&formulario=PROSPECTOS.
•Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2010;23(1-2):73-80.
•Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, et al. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop. 2008 Jun;28(4):483-7.
•Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, Yordam N. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab. 2008;21(1):63-72.
•Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006;39(4):901-6.
•Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr. 2006;148(4):456-60.
•Vallo A, Rodriguez-Leyva F, Rodríguez Soriano J. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr. 2006;95(3):332-9.
•Wagner S, Poirot I, Vuillerot C, Berard C. Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders. Ann Phys Rehabil Med. 2011;54(6):348-58.
•Bachrach SJ, Kecskemethy HH, Harcke HT, Hossain J. Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol. 2010;52(9):837-42.
•Howe W, Davis E, Valentine J. Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. Dev Neurorehabil. 2010;13(1):31-6.
•Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol. 2006;48(9):709-12.
•Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthop Belg. 2005;71(1):91-7.
•Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003;88(10):4569-75.
•Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:929-37.
•Kos M, Luczak K, Godzinski J, Klempous J. Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg. 2004;32(1):10-5.
•Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr. 2000;89(2):188-93.
•Compeyrot-Lacassagne S, Rosenberg AM, Babyn P, Laxer RM. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol. 2007;34(7):1585-9.
•Al-Mayouf SM, Madi SM, Bin-Abbas BS. Cyclic intravenous pamidronate treatment in children with nodulosis, arthropathy and osteolysis syndrome. Ann Rheum Dis. 2006;65(12):1672-3.
•Kerrison C, Davidson JE, Cleary AG, Beresford MW. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford). 2004;43(10):1246-51.
•Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatr Blood Cancer. 2010;54(7):934-40.
•Leblicq C, Laverdière C, Décarie JC, Delisle JF, Isler MH, Moghrabi A, et al. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep 21. doi: 10.1002/pbc.24313.
•Pastore S, Londero M, Barbieri F, Di Leo G, Paparazzo R, Ventura A. Treatment with pamidronate for osteoporosis complicating long-term intestinal failure. J Pediatr Gastroenterol Nutr. 2012;55(5):615-8.
•Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(1):135-40.
•Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, et al. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatr Endocrinol Rev. 2008;6 Suppl 1:144-8.
•Kanumakala S, Boneh A, Zacharin M. Pamidronate treatment improves bone mineral density in children with Menkes disease. J Inherit Metab Dis. 2002;25(5):391-8.
•Sumník Z, Land C, Rieger-Wettengl G, Körber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res. 2004;61(3):137-42.
•Schmid I, Stachel D, Schön C, Bauer M, Haas RJ. Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children. Klin Padiatr. 2001;213(1):30-4.
•Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in
•children. Med Pediatr Oncol. 1998;30(2):117-21.
•Gurkan F, Davutoglu M, Bosnak M, Ece A, Dikici B, Bilici M, et al. Pamidronate treatment in acute vitamin D intoxication. J Endocrinol Invest. 2004;27(7):680-2.
•Bryowsky JJ, Bugnitz MC, Hak EB. Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition. Pharmacotherapy. 2004;24(7):939-44.
•Sangun O, Dundar BN, Erdogan E. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy. J Pediatr Endocrinol Metab. 2011;24(1-2):69-70.
•Roderick M, Shah R, Finn A, Ramanan AV. Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging. Rheumatology (Oxford). 2014;53(11):1973-6.
Fecha de actualización: Junio 2016.
La información disponible en cada una de las fichas del Pediamécum ha sido revisada por el Comité de Medicamentos de la Asociación Española de Pediatría y se sustenta en la bibliografía citada. Estas fichas no deben sustituir en ningún caso a las aprobadas para cada medicamento por la Agencia Española del Medicamento y Productos Sanitarios (AEMPS) o la Agencia Europea del Medicamento (EMA).
Envíenos sus observaciones